| REVIEW ARTICLE |
|
| Year : 2017 | Volume
: 3
| Issue : 1 | Page : 4-10 |
|
|
Itraconazole: What clinicians should know?
Piet De Doncker1, Sushil Pande2, Ute Richarz3, Nishant Garodia4
1 Infectious Disease, Janssen Pharmaceutica, Beerse, Belgium
2 Department of Dermatology, NKP Salve Institute of Medical Science, Nagpur, Maharashtra, India
3 GCSO Janssen GMA Established Brand, Zug, Switzerland
4 Janssen Medical Affairs, Johnson and Johnson Pvt. Ltd., Mumbai, Maharashtra, India
Correspondence Address:
Nishant Garodia
Janssen Medical Affairs, Johnson and Johnson Pvt. Ltd., 501 Arena Space, Jogeshwari (E), Mumbai, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijdd.ijdd_20_17
|
|
|
Our purpose in assembling this paper is 2-fold. First, we hope to review in-depth the properties on itraconazole pellet-capsules and what clinicians should know when considering oral itraconazole and discuss the potential value of treating superficial dermatophyte infections with oral antifungal therapy. Second, we hope to address some of the concerns of the recent epidemic of chronic recalcitrant widespread dermatophytosis in India, with emphasis on better treatment but also considering some of the necessary prophylaxis hygiene measures. An in-depth review of itraconazole (as pellet-capsules), a triazole antifungal will be presented with focus on the pharmacokinetic properties which lead to the development of the 1-week pulse dosing for skin and nail infections. Finally, recommendations for best usage of itraconazole pellet-capsules for management of dermatophytosis will be summarized in this paper. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
